CCTA-1523

Cat. No. M49911

All AbMole products are for research use only, cannot be used for human consumption.

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

CCTA-1523 is a potent, selective, reversible, and orally active ABCG2 inhibitor.CCTA-1523 exhibits cytotoxicity and anticancer activity.

Molecular Weight	340.20
Formula	C16H15Cl2NO3
CAS Number	1616271-41-0
Storage	Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month

Related BCRP/ABCG2/MXR/ABCP Products
Ac32Az19 Ac32Az19 is a potent, nontoxic, and highly selective BCRP inhibitor with an EC50 value of 13 nM in BCRP overexpressing HEK293/R2 cells.
ML230 ML230 is a selective inhibitor of the ATP-binding transporter subtype ABCG2, and its inhibitory effect on ABCG2 was 36 times that of ABCB1, with EC50 values of 0.13 μM and 4.65 μM, respectively.
(S)-ML753286 (S)-ML753286 is a breast cancer resistance protein (BCRP) inhibitor that inhibits BCRP efflux transporter protein with an IC50 of 0.6 μM.
Efflux inhibitor-1 Efflux inhibitor-1 is a pyrazolo[1,5-a]pyrimidine efflux inhibitor that also selectively targets ABCG2, with IC50s of 0.45 μM and 2.17 μM, respectively.
Zamicastat Zamicastat is a dopamine β-hydroxylase (DBH) inhibitor that crosses the blood-brain barrier and causes central and peripheral effects. In addition, Zamicastat is a concentration-dependent dual P-gp and BCRP inhibitor with IC50 values of 73.8 μM and 17.0 μM, respectively.

Catalog